Covid-19: India’s slow moving treatment guidelines are misleading and harming patients

Author:

Pulla Priyanka

Publisher

BMJ

Subject

General Engineering

Reference13 articles.

1. Indian Council of Medical Research. Evidence based advisory to address inappropriate use of convalescent plasma in covid-19 patients. 17 Nov 2020. https://www.icmr.gov.in/pdf/covid/techdoc/ICMR_ADVISORY_Convalescent_plasma_17112020_v1.pdf.

2. The REMAP-CAP Investigators . Interleukin-6 receptor antagonists in critically ill patients with covid-19: preliminary report. MedRxiv 2021.01.07.21249390 [Preprint]. https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v2.

3. Pulla P. Is favipiravir good for covid-19? Clinical trial says no, press release says yes. The Wire 2020 Nov 25. https://science.thewire.in/the-sciences/favipiravir-glenmark-open-label-trial-primary-endpoints-efficacy-cure-times-misleading-press-release.

4. Kumar S de Souza R Nadkar M . A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of itolizumab in moderate to severe ARDS patients due to covid-19. medRxiv 2020.12.01.20239574 [Preprint]. https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1.

5. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. COVID-19 pandemic, medications, and antimicrobial resistance in India: A cascade of events;Journal of Integrative Medicine and Public Health;2023-07

2. Importance of critical appraisal skills training in medical students;The National Medical Journal of India;2023-04-28

3. COVID-19 therapies for inpatients: a review and quality assessment of clinical guidelines;ERJ Open Research;2022-09-16

4. Interpretation of data of case- sheets from COVID-19 ward;Journal of Family Medicine and Primary Care;2022

5. Recommendations by experts fail to impress;Indian Journal of Medical Sciences;2021-12-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3